Intangible assets (Details) (Bristol-Myers Squibb Company, FV-100, USD $)	1 Months Ended	3 Months Ended
Aug. 31, 2012	Sep. 30, 2012
Bristol-Myers Squibb Company \| FV-100
Asset Purchase Agreement
Initial payment in terms of agreement	$ 1,000,000
Milestone of aggregate net sales	125,000,000
Base payment to research and development expense		$ 1,000,000

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References+ Details